Skip to main content

A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma.

Zhang Y, Urquijo MA, Zitnay RG, Marks K, Belote RL, Hansen MMK, Ferita M, Neuendorf HM, Liu T, Smith EA, Mehrabad EM, Hejna M, Moustafa TE, Lange D, Hu M, Vand-Rajabpour F, Done A, Becker CA, Lieberman M, Chang M, Lohman BK, Stubben CJ, Reeves MQ, Zhang X, Weinberger LS, VanBrocklin MW, Deacon DC, Grossman D, Spike BT, Lex A, Boyle GM, Kulkarni R, Zangle TA, Judson-Torres RL
Cell Rep. 2025 Dec 23;44(12):116675. doi: 10.1016/j.celrep.2025.116675. Epub 2025 Dec 15. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

ID Plasmid Purpose
153321pROM-POU3F2p-mCherry-NeoExpresses mCherry from the POU3F2 promoter

Antibodies from Article